ArticleEndoscopy international open2025
Outcomes of endoscopic submucosal dissection for treatment of superficial anal squamous cell carcinoma: Multicenter international experience.
Article in Endoscopy international open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endoscopic characteristics and clinical outcomes of squamous intraepithelial lesions and squamous cell carcinoma in the anal canal.Endoscopy international open · 2026Article
- Is endoscopic submucosal dissection a first-line treatment for anal squamous cell carcinoma?Endoscopy international open · 2026Article
Corrections and comments
- Commented on by
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and study aims: Data on feasibility of endoscopic submucosal dissection (ESD) for treatment of superficial anal squamous cell carcinoma are limited. This study aimed to evaluate outcomes of ESD in this anatomical location. Patients and methods: This was a multicenter retrospective study including patients who underwent ESD for treatment of superficial ASCC. Results: Twenty-three patients with superficial ASCC were included. Median lesion size was 24 mm (range, 9-65 mm) and median procedure time was 62 minutes (range, 26-210 minutes). Accuracy of optical diagnosis using Japanese Endoscopic Society Intrapapillary capillary loops (IPCLs) classification to predict final histology was 63.6%. En bloc and R0 resection were achieved in 22 (95.6%) and 18 patients (78.3%), respectively. The curative resection rate was 73.9% (17/23). Three patients received additional complementary treatment. Delayed bleeding was observed in four patients (17.4%), two of whom required endoscopic hemostasis. Anal pain was reported in nine patients (39.1%) and was effectively managed with analgesics. Fecal incontinence and anal stenosis both occurred in one patient during the perioperative period. During median follow-up of 10.1 months (range, 0-69.6 months), no recurrences were observed. Conclusions: ESD is a feasible and effective treatment for superficial ASCC. Adverse events were successfully managed with medical or endoscopic therapy. ESD should be considered as first-line resection technique to prevent recurrence while preserving anal sphincter function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.